Business Context and Reporting Period
This Form 8-K filing by Kura Oncology, Inc. (Delaware) was submitted on October 13, 2015, with the report date of October 14, 2015. The filing addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new director and associated compensation.
Material Changes
The primary material change reported is the appointment of Thomas Malley to the Board of Directors on October 13, 2015. His term expires at the next annual meeting of stockholders. No other material changes to operations or financial status are disclosed in this document.
Guidance, Outlook, and Compensation Details
Management commentary is limited to the announcement of the new director. The filing details the following compensatory arrangements for Mr. Malley:
- Cash Retainer: $50,000 annually.
- Equity Grant: Option to purchase 30,000 shares of common stock at fair market value on the date of appointment.
- Vesting Schedule: Vests annually over a three-year period.
- Acceleration: Vesting accelerates in the event of a change in control during the period of Board service.
- Agreements: Mr. Malley has entered into the Company's standard Indemnification Agreement.
No financial guidance, outlook, or specific risk factors are disclosed in this filing.
Investor Verification Checklist
- Verify the fair market value of the stock on October 13, 2015, to calculate the total value of the 30,000 share option grant.
- Review the attached Press Release (Exhibit 99.1) for additional context on Mr. Malley's background and qualifications.
- Confirm the date of the next annual meeting of stockholders to determine the exact expiration of Mr. Malley's term.
- Check subsequent filings for any changes to the Board composition or compensation policies.